Psychiatry | Page 7 of 61 | Links Medicus Content Curation & Alerts in Medicine

📢New placebo-controlled, double-blind, RCT: Single-dose #psilocybin-assisted therapy in #majordepressivedisorder

Results suggest that a single dose of psilocybin significantly reduces depressive symptoms compared to placebo for at least 2 weekshttps://t.co/Ps43rxHv6r pic.twitter.com/Qc8xSgnalw

— eClinicalMedicine – The Lancet Discovery Science (@eClinicalMed) January 18, 2023

Review | Young-onset dementia diagnosis, management and care

24 Feb, 2023 | 13:37h | UTC

Young-onset dementia diagnosis, management and care: a narrative review – The Medical Journal of Australia

M-A | Metabolic side effects in persons with schizophrenia during mid- to long-term treatment with antipsychotics

23 Feb, 2023 | 13:26h | UTC

Summary: This study aimed to evaluate the mid- to long-term metabolic side effects of 31 antipsychotics in persons with schizophrenia by analyzing 137 eligible randomized controlled trials with 35,007 participants. The primary outcome was weight gain, with secondary outcomes including fasting glucose, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides. The study found that antipsychotic drugs differ in their propensity to induce metabolic side effects. Chlorpromazine, clozapine, olanzapine, and zotepine produced the most weight gain. The confidence in the evidence ranged from low to moderate. The study suggests that differences in weight gain were more pronounced than previously published short-term data and that weight gain is most pronounced at the beginning of treatment and then remains stable.

Article: Metabolic side effects in persons with schizophrenia during mid- to long-term treatment with antipsychotics: a network meta-analysis of randomized controlled trials – World Psychiatry (free for a limited period)

SR | Antipsychotic exposure is an independent risk factor for breast cancer

17 Feb, 2023 | 12:41h | UTC

Antipsychotic exposure is an independent risk factor for breast cancer: A systematic review of epidemiological evidence – Frontiers in Oncology

Pediatric edible cannabis exposures and acute toxicity in the US: 2017–2021

16 Feb, 2023 | 15:00h | UTC

Pediatric Edible Cannabis Exposures and Acute Toxicity: 2017–2021 – Pediatrics

Commentaries:

The Number of American Kids Eating Cannabis Has Surged Dramatically – Science Alert

2017 to 2021 Saw Increase in Pediatric Edible Cannabis Exposure – HealthDay

M-A | Cost-effectiveness of internet interventions compared with treatment as usual for people with mental disorders

16 Feb, 2023 | 14:43h | UTC

Cost-effectiveness of Internet Interventions Compared With Treatment as Usual for People With Mental Disorders: Systematic Review and Meta-analysis of Randomized Controlled Trials – Journal of Medical Internet Research

SR | The effect of parental leave on parents’ mental health

15 Feb, 2023 | 15:44h | UTC

The effect of parental leave on parents’ mental health: a systematic review – The Lancet Public Health

Invited Commentary: Paid parental leave and mental health: the importance of equitable policy design – The Lancet Public Health

News Release: Generous parental leave schemes protect against poorer mental health – Stockholm University / News Medical

Consensus Paper | ED management of patients with alcohol intoxication, alcohol withdrawal, and alcohol use disorder

14 Feb, 2023 | 11:05h | UTC

Emergency Department Management of Patients with Alcohol Intoxication, Alcohol Withdrawal, and Alcohol Use Disorder: A White Paper Prepared for the American Academy of Emergency Medicine – The Journal of Emergency Medicine

Diagnostic Study | Level of attention to motherese speech as an early marker of autism spectrum disorder

14 Feb, 2023 | 11:04h | UTC

Summary: A study was conducted to determine if levels of attention to motherese speech can be used as a diagnostic marker for autism spectrum disorder (ASD) and if they are associated with social and language abilities. The study involved 653 toddlers aged 12 to 48 months and used gaze-contingent eye tracking to measure attention to motherese speech. The results showed that toddlers without ASD had high levels of fixation on motherese speech, while those with ASD had significantly reduced levels. If a toddler fixated on motherese speech at or below 30%, the probability of them being accurately diagnosed with ASD was 94%, and it was also associated with reduced social and language abilities. The findings suggest that attention to motherese speech may be a diagnostic and prognostic marker of ASD.

(By ChatGPT, reviewed and edited)

Article: Level of Attention to Motherese Speech as an Early Marker of Autism Spectrum Disorder – JAMA Network Open

Commentaries:

Attention to motherese speech is a promising early diagnostic marker for autism spectrum disorder – News Medical

Toddlers’ Attention to ‘Motherese’ Could Give Clues to Autism – HealthDay

Cohort Study | In utero exposure to ADHD medication does not seem to result in worse offspring neurodevelopmental outcomes

14 Feb, 2023 | 10:54h | UTC

Summary: The authors conducted a study to investigate the long-term effects of in utero exposure to ADHD medication (methylphenidate, amphetamine, dexamphetamine, lisdexamphetamine, modafinil, atomoxetine, clonidine) on offspring. The study followed 1,068,073 liveborn singletons from 1998 to 2018 and compared the outcomes of children whose mothers continued or discontinued ADHD medication during pregnancy. The main outcomes were neurodevelopmental psychiatric disorders, impairments in vision or hearing, epilepsy, seizures, or growth impairment during childhood or adolescence. After adjustment for demographic and psychiatric characteristics of the mother, no increased risk of any developmental disorders was found in offspring exposed to ADHD medication compared to those not exposed. The results provide reassurance for women with ADHD who depend on medication and consider continuing it during pregnancy.

(By ChatGPT, reviewed and edited)

Article: In utero exposure to ADHD medication and long-term offspring outcomes – Molecular Psychiatry (link to abstract – $ for full-text)

News Release: Study: Pregnant women on ADHD medications shouldn’t worry about pediatric neurodevelopmental disorders – The Mount Sinai Hospital

Commentary from the author on Twitter (thread – click for more)

In-utero exposure to ADHD medication is not associated with long-term adverse neurodevelopmental disorders and growth restriction in the offspring.

Read the thread below 🧵on our new paper just published in @molpsychiatry
👉 https://t.co/MKZ0aeFnhU #ADHD

— Kathrine Bang Madsen (@Kathrine_BaMa) February 9, 2023

Consensus Paper | Biological treatment of bipolar disorder during the acute, maintenance, and mixed phases

10 Feb, 2023 | 13:50h | UTC

Taiwan consensus on biological treatment of bipolar disorder during the acute, maintenance, and mixed phases: The 2022 update – Asian Journal of Psychiatry

Bipolar depression: the clinical characteristics and unmet needs of a complex disorder – Current Medical Research and Opinion

Bipolar disorder: assessment and management – National Institute for Health and Care Excellence

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder – Bipolar Disorders

Systematic Review: Treatment for Bipolar Disorder in Adults – Agency for Healthcare Research and Quality (free)

Korean Medication Algorithm Project for Bipolar Disorder 2022: comparisons with other treatment guidelines

10 Feb, 2023 | 13:49h | UTC

Korean Medication Algorithm Project for Bipolar Disorder 2022: Comparisons with Other Treatment Guidelines – Clininical Psychopharmacology and Neuroscience

Cohort Study | Associations between betablockers and psychiatric and behavioral outcomes

10 Feb, 2023 | 13:47h | UTC

Associations between β-blockers and psychiatric and behavioural outcomes: A population-based cohort study of 1.4 million individuals in Sweden – PLOS Medicine

Phase 1b RCT | Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia

8 Feb, 2023 | 12:23h | UTC

Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial – The Lancet (link to abstract – $ for full-text)

Commentary: Emraclidine is safe and well-tolerated for the treatment of schizophrenia – 2 Minute Medicine

Commentary on Twitter (thread – click for more)

Up to 1/3 of patients with #schizophrenia do not respond to current treatments, and there remains a need for novel approaches that balance efficacy against side-effects.

This phase 1b study assessed the safety and tolerability of emraclidine 🧵 https://t.co/WMcArqDK1C

— The Lancet (@TheLancet) December 28, 2022

M-A | Efficacy of treatments for children, adolescents, and young adults with Tourette’s syndrome

8 Feb, 2023 | 12:13h | UTC

Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette’s syndrome: a systematic review and network meta-analysis – The Lancet Child & Adolescent Health (link to abstract – $ for full-text)

Commentary on Twitter

Treatment recommendations are inconsistent for #Tourette syndrome.

New network meta-analysis by @luis_farhat & team shows that #antipsychotics are the most efficacious, while α-2 agonists are also more efficacious than placebohttps://t.co/awYHWUJA3v

— The Lancet Child & Adolescent Health (@LancetChildAdol) December 19, 2022

Cohort Study | The use of 5-alfa-reductase inhibitors may increase the risk of depression, but not dementia

7 Feb, 2023 | 13:35h | UTC

Association of 5α-Reductase Inhibitors With Dementia, Depression, and Suicide – JAMA Network Open

Commentary: 5α-Reductase Inhibitors Linked to Depression, but Not Dementia – HealthDay

Cohort Study | Association between antiepileptic drugs and incident Parkinson disease

3 Feb, 2023 | 13:51h | UTC

Association Between Antiepileptic Drugs and Incident Parkinson Disease in the UK Biobank – JAMA Neurology (link to abstract – $ for full-text)

Commentary on Twitter

This study using @uk_biobank data found evidence of an association between anti-epileptic drugs and incident #ParkinsonDisease. https://t.co/58PMlWQUYU

— JAMA Neurology (@JAMANeuro) December 28, 2022

M-A | Depressive symptoms in individuals with persistent postconcussion symptoms

3 Feb, 2023 | 13:48h | UTC

Depressive Symptoms in Individuals With Persistent Postconcussion Symptoms: A Systematic Review and Meta-Analysis – JAMA Network Open

Commentary: Significant Link Seen for Persistent Postconcussion Symptoms, Depression – HealthDay

Commentary on Twitter

Patients with persistent postconcussion symptoms are at increased risk of experiencing symptoms of depression. Post-injury support and interventions targeting mental health are necessary for optimal outcomes. https://t.co/7KiletIsf6

— JAMA Network Open (@JAMANetworkOpen) December 27, 2022

Efficacy, safety, and tolerability of antidepressants for pain in adults: overview of systematic reviews

2 Feb, 2023 | 15:05h | UTC

Efficacy, safety, and tolerability of antidepressants for pain in adults: overview of systematic reviews – The BMJ

Editorial: Rethinking use of medicines for chronic pain – The BMJ

News Release: Antidepressants use for chronic pain on the rise, but are they effective? – University of Sidney

Commentary from the author on Twitter (thread – click for more)

Out today in @bmj_latest

We reviewed the evidence on the efficacy of antidepressants for pain in adults

We showed that antidepressants are effective for some pain conditions, but for most they are either ineffective or evidence is inconclusivehttps://t.co/E2XVQ9oGUQ
🧵 pic.twitter.com/kBo7eAyeCP

— Giovanni Ferreira (@giovanni_ef) February 1, 2023